Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
JERSEY CITY, N.J., Aug. 07, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the Canaccord Genuity Growth Conference at the InterContinental Boston on Thursday, August 10, 2017 at 11:30 a.m. ET.
A live webcast will be available on the investors section of the Company’s website: www.SCYNEXIS.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel oral and intravenous triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
